Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginkgo Bioworks HoldingsDNA -5.64%60 PB Ratio is 0.99 as of Aug. 19, 2026, which is 38% below its 10-year median of 1.60. GuruFocus rates DNA with a GF Score™ of 60/100 and a GF Value™ of $5.95 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,216 Biotechnology companies, Ginkgo Bioworks Holdings ranks better than 82.57% on this metric.
The historical rank and industry rank for Ginkgo Bioworks Holdings's PB Ratio or its related term are showing as below:
DNA'
s PB Ratio Range Over the Past 10 Years
Min: 0.35 Med: 1.6 Max: 13.37
Current: 0.99
During the past 7 years, Ginkgo Bioworks Holdings's highest PB Ratio was 13.37. The lowest was 0.35. And the median was 1.60.
DNA's PB Ratio is ranked better than 82.57% of 1216
companies
in the Biotechnology industry
Industry Median: 2.895
vs DNA: 0.99
During the past 12 months, Ginkgo Bioworks Holdings's average Book Value Per Share Growth Rate was -40.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 45.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Ginkgo Bioworks Holdings was 313.10% per year. The lowest was -38.00% per year. And the median was -29.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ginkgo Bioworks Holdings (DNA) has a PB Ratio of 0.99 as of Aug. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ginkgo Bioworks Holdings and its competitors. This is 38% below median its historical median of 1.60. Over the past decade, Ginkgo Bioworks Holdings' PB Ratio has ranged from 0.35 to 13.37. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #212 out of 1216 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Ginkgo Bioworks Holdings' PB Ratio too high?
Ginkgo Bioworks Holdings' current PB Ratio of 0.99 is 38% below median its 10-year median of 1.60. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 13.37. The Biotechnology industry median PB Ratio is 2.90. Ginkgo Bioworks Holdings' value of 0.99 is 65.8% below this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #212 out of 1216 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' PB Ratio compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #212 out of 1216 companies for PB Ratio. This places Ginkgo Bioworks Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.90. Ginkgo Bioworks Holdings' value of 0.99 is 65.8% below this benchmark. Historically, Ginkgo Bioworks Holdings' own PB Ratio has ranged from 0.35 to 13.37 over the past decade. While the company's 10-year median is 1.60 vs. the industry median of 2.90, Ginkgo Bioworks Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current PB Ratio of 0.99 is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current PB Ratio is 0.99, which is 38% below median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (DNA) is currently considered Fairly Valued. The stock's GF Value™ is $5.95, compared to a current price of $6.53 — trading 9.7% above its estimated fair value. The current PB Ratio is 0.99, which is 38% below median its 10-year median of 1.60 and 65.8% below the Biotechnology industry median of 2.90. Ginkgo Bioworks Holdings' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNA), the current PB Ratio is 0.99 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of $6.53 is trading 9.7% above its estimated GF Value™ of $5.95.
GuruFocus considers Ginkgo Bioworks Holdings to be Fairly Valued.
Key valuation signals for DNA:
PB Ratio: 0.99 (38% below median its 10-year median of 1.60)
GF Value™: $5.95 vs. price of $6.53 (9.7% above fair value)
Industry Position: 65.8% below the Biotechnology median (#212 of 1216)
No single metric tells the full story. See the DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
60GF Score
Get the complete analysis for DNA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNA has been successfully added to your 
